Herpes Simplex Virus Type 1 Clinical Isolates Respond to UL29-Targeted siRNA Swarm Treatment Independent of Their Acyclovir Sensitivity

Herpes Simplex Virus Type 1 Clinical Isolates Respond to UL29-Targeted siRNA Swarm Treatment Independent of Their Acyclovir Sensitivity

Acyclovir is the drug of choice for the treatment of herpes simplex virus (HSV) infections. Acyclovir-resistant HSV strains may emerge, especially during long-term drug use, and subsequently cause difficult-to-treat exacerbations. Previously, we set up a novel treatment approach, based on enzymatica...

Full description

Bibliographic Details
Main Authors: Kiira Kalke, Jenni Lehtinen, Jelena Gnjatovic, Liisa M. Lund, Marie C. Nyman, Henrik Paavilainen, Julius Orpana, Tuomas Lasanen, Fanny Frejborg, Alesia A. Levanova, Tytti Vuorinen, Minna M. Poranen, Veijo Hukkanen
Format: Article
Language:English
Published: MDPI AG 2020-12-01
Series:Viruses
Subjects:
herpes simplex virus
antiviral
RNAi
siRNA
acyclovir
acyclovir resistance
Online Access:https://www.mdpi.com/1999-4915/12/12/1434

Similar Items

Similar Items